Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | WD repeat domain, putative | 0.0206 | 1 | 1 |
Toxoplasma gondii | exonuclease III APE | 0.0019 | 0 | 0.5 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0019 | 0 | 0.5 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0019 | 0 | 0.5 |
Onchocerca volvulus | 0.0206 | 1 | 0.5 | |
Brugia malayi | Muscleblind-like protein | 0.0148 | 0.6914 | 0.6914 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0019 | 0 | 0.5 |
Echinococcus multilocularis | muscleblind protein 1 | 0.0148 | 0.6914 | 0.6914 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0019 | 0 | 0.5 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0019 | 0 | 0.5 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0019 | 0 | 0.5 |
Echinococcus multilocularis | protein will die slowly | 0.0206 | 1 | 1 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0019 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0148 | 0.6914 | 0.6914 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0019 | 0 | 0.5 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0019 | 0 | 0.5 |
Echinococcus granulosus | muscleblind protein | 0.0148 | 0.6914 | 0.6914 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0019 | 0 | 0.5 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0019 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0148 | 0.6914 | 0.6914 |
Echinococcus multilocularis | muscleblind protein | 0.0148 | 0.6914 | 0.6914 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0019 | 0 | 0.5 |
Echinococcus granulosus | protein will die slowly | 0.0206 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0206 | 1 | 1 |
Loa Loa (eye worm) | WD40 repeat protein | 0.0206 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.